Subtype
Diffuse Midline Glioma
CI-CAN-00005114Explore in graph →
61 active trials1 approved drugs15 evidence items
- NCIt
- C182151
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005114Explore in graph →
Clinical trials
129 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (23)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01165333 | Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma(CILENT) | completed | Phase 1 | 32 | Centre Oscar LambretOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07455045 | A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG) | not yet recruiting | Phase 1 | 40 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 6, 2026 |
| NCT05762419 | FUS Etoposide for DMG | recruiting | Phase 1 | 10 | Columbia UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07331064 | Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor(GABRIEL) | not yet recruiting | Phase 1 | 15 | Sarah RumlerOTHER | 0 | Jan 9, 2026 | clinicaltrials |
| NCT04049669 | Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG | active not recruiting | Phase 2 | 130 | Theodore S. JohnsonOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04295759 | INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas | completed | Phase 1 | 13 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jan 5, 2026 | clinicaltrials |
| NCT04541082 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | recruiting | Phase 1 | 102 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05259605 | Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification | recruiting | — | 1,650 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Dec 17, 2025 | clinicaltrials |
| NCT05956821 | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | recruiting | Phase 1 / Phase 2 | 20 | University of MiamiOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05768880 | Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors | active not recruiting | Phase 1 | 72 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT03396575 | Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)(BRAVO) | terminated | Phase 1 | 11 | University of FloridaOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT03101813 | International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository | recruiting | — | 1,500 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT02742883 | A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG) | suspended | Phase 2 | 1 | Burzynski Research InstituteOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT03330197 | A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG | terminated | Phase 1 / Phase 2 | 6 | Alaunos TherapeuticsINDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | terminated | Phase 1 | 40 | Actuate Therapeutics Inc.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT03893487 | Fimepinostat in Treating Brain Tumors in Children and Young Adults(PNOC016) | active not recruiting | Early Phase 1 | 30 | Sabine Mueller, MD, PhDOTHER | 2 | Jul 11, 2025 | clinicaltrials |
| NCT06896110 | Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma | enrolling by invitation | Phase 1 | 34 | Andrew P. GrovesOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04804709 | Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG) | terminated | Phase 1 | 5 | Columbia UniversityOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT04749641 | Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma(ENACTING) | completed | Phase 1 | 16 | Yang ZhangOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT04250064 | A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma(LoBULarDIPG) | recruiting | Phase 2 | 40 | Tata Memorial CentreOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT03690869 | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | terminated | Phase 1 / Phase 2 | 57 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 8, 2025 | clinicaltrials |
| NCT02420613 | Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma | completed | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06221553 | Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG(CMD03DIPG) | recruiting | Phase 1 | 9 | Chulalongkorn UniversityOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT02992015 | Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma | completed | Early Phase 1 | 2 | University of Colorado, DenverOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT03416530 | ONC201 in Pediatric H3 K27M Gliomas | terminated | Phase 1 | 134 | Jazz PharmaceuticalsINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05298995 | GD2-CAR T Cells for Pediatric Brain Tumours | recruiting | Phase 1 | 54 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT02960230 | H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas | completed | Phase 1 / Phase 2 | 50 | Sabine Mueller, MD, PhDOTHER | 2 | Jan 22, 2025 | clinicaltrials |
| NCT03709680 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | active not recruiting | Phase 2 | 128 | PfizerINDUSTRY | 14 | Jan 14, 2025 | clinicaltrials |
| NCT04758533 | Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy(AloCELYVIR) | active not recruiting | Phase 1 / Phase 2 | 13 | Hospital Infantil Universitario Niño Jesús, Madrid, SpainOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT02525692 | Oral ONC201 in Adult Recurrent Glioblastoma | terminated | Phase 2 | 84 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT04771897 | A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)(KONQUER) | terminated | Phase 1 | 10 | Bexion Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT05518838 | Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered | no longer available | — | — | Oblato, Inc.INDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT05123534 | A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG | suspended | Phase 2 | 15 | SonALAsense, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT01106794 | Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma | recruiting | — | 100 | Children's National Research InstituteOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06439849 | Single Patient Compassionate Use / Expanded Access L-S-Gboxin (Lyophilized Form of S-Gboxin) for the Treatment of Diffuse Midline Glioma(TRIANGLE) | no longer available | — | — | Petrov, AndreyOTHER | 0 | Jul 16, 2024 | clinicaltrials |
| NCT06140719 | xPedite: A Study to Expedite DIPG and DMG Research | recruiting | — | 400 | xCuresINDUSTRY | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06305910 | CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults | recruiting | Phase 1 | 24 | OX2 TherapeuticsINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05717699 | Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma | recruiting | Phase 1 | 18 | Capital Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05717712 | Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma | recruiting | Phase 1 | 18 | Capital Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04341311 | Phase I Study of Marizomib + Panobinostat for Children With DIPG(DIPG) | terminated | Phase 1 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT01922076 | Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas | completed | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 2 | Jan 31, 2024 | clinicaltrials |
| NCT04264143 | CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas | completed | Phase 1 | 9 | Luca SzalontayOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT03620032 | Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses(DIPG) | unknown | Phase 2 | 54 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT02644460 | Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors(AflacST1501) | completed | Phase 1 | 53 | Emory UniversityOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06093165 | RE-irradiation of Diffuse MIdline Glioma paTients(REMIT) | not yet recruiting | N/A | 59 | Rigshospitalet, DenmarkOTHER | 0 | Oct 23, 2023 | clinicaltrials |
| NCT03841435 | Hypofractionated Radiotherapy for Recurrent DIPG | completed | N/A | 5 | University of CincinnatiOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT04532229 | Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children | unknown | Phase 3 | 48 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05063357 | 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma | withdrawn | Phase 1 | 0 | Y-mAbs TherapeuticsINDUSTRY | 0 | Jun 26, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Mar 16, 2026source: clinicaltrials